These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27106721)

  • 1. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.
    Clough GF; McCormick KG; Scorletti E; Bhatia L; Calder PC; Griffin MJ; Byrne CD
    Diabetologia; 2016 Jul; 59(7):1422-1429. PubMed ID: 27106721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.
    McCormick KG; Scorletti E; Bhatia L; Calder PC; Griffin MJ; Clough GF; Byrne CD
    Diabetologia; 2015 Aug; 58(8):1916-25. PubMed ID: 26021488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
    Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Hodson L; Moyses HE; Calder PC; Byrne CD;
    Hepatology; 2014 Oct; 60(4):1211-21. PubMed ID: 25043514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
    Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
    Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.
    Manousopoulou A; Scorletti E; Smith DE; Teng J; Fotopoulos M; Roumeliotis TI; Clough GF; Calder PC; Byrne CD; Garbis SD
    Clin Nutr; 2019 Aug; 38(4):1952-1955. PubMed ID: 30172659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
    Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
    Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
    Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension.
    Woodman RJ; Mori TA; Burke V; Puddey IB; Watts GF; Beilin LJ
    Am J Clin Nutr; 2002 Nov; 76(5):1007-15. PubMed ID: 12399272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
    Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
    BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
    Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
    J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women.
    Oya J; Nakagami T; Sasaki S; Jimba S; Murakami K; Kasahara T; Wasada T; Sekiguchi H; Hasegawa M; Endo Y; Iwamoto Y
    Eur J Clin Nutr; 2010 Oct; 64(10):1179-85. PubMed ID: 20683463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial.
    Hoogeveen EK; Geleijnse JM; Kromhout D; Giltay EJ
    Eur J Prev Cardiol; 2014 Nov; 21(11):1429-36. PubMed ID: 23774275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.